1. Indications and Usage
\nLocally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC):
\nIndicated for adults with mTNBC who have received two or more prior systemic therapies, at least one of them for metastatic disease.
\nHR-Positive, HER2-Negative Metastatic Breast Cancer:
\nIndicated for adults with unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer who have received endocrine-based therapy and at least two prior systemic therapies.
\nLocally Advanced or Metastatic Urothelial Cancer (la\/muVa):
\nIndicated for adults with la\/muVa who have previously been treated with a PD-1 or PD-L1 inhibitor and a platinum-containing chemotherapy.
\n2. Dosage and Administration
\nRoute of Administration:
\nIntravenous Infusion ONLY. Do not administer as an IV push or bolus.
\nRecommended Dosage:
\nDose: 10 mg\/kg administered intravenously on Day 1 and Day 8 of each 21-day cycle.
\nPremedication: Administer antiemetics (e.g., ondansetron) prior to each infusion.
\nAdministration Instructions:
\nDilute with 0.9% Sodium Chloride Injection to a concentration of 1.1 mg\/mL to 3.4 mg\/mL.
\nInfuse over at least 3 hours for the first dose; subsequent doses may be infused over at least 1 hour if no hypersensitivity occurred.
\n3. Mechanism of Action
\nADC Technology:
\nSacituzumab govitecan is an antibody-drug conjugate targeting TROP-2, a cell surface protein expressed in many epithelial tumors.
\nPayload Release:
\nUpon binding to TROP-2, the drug is internalized and degraded in lysosomes, releasing the active metabolite SN-38. SN-38 acts as a potent topoisomerase I inhibitor, causing DNA damage and tumor cell apoptosis.
\n4. Safety and Warnings
\nNeutropenia:
\nMay cause severe or life-threatening neutropenia. Monitor complete blood counts prior to each dose. Administer G-CSF if necessary.
\nDiarrhea:
\nMay cause severe or life-threatening diarrhea. Monitor patients for signs of diarrhea and provide supportive care (e.g., loperamide, atropine).
\nHypersensitivity Reactions:
\nMonitor patients during and for 1 hour after infusion.
\n5. Adverse Reactions
\nMost Common:
\nNeutropenia, diarrhea, nausea, fatigue, anemia, vomiting, constipation, rash, alopecia, pyrexia, and decreased appetite.
\n6. Drug Interactions
\nUGT1A1 Modulators:
\nAvoid concomitant use of UGT1A1 inhibitors (e.g., atazanavir) or inducers, as they may increase or decrease SN-38 exposure, respectively.
\n7. Pharmaceutical Information
\nChemical Composition:
\nActive Ingredient: Sacituzumab Govitecan-hziy.
\nStorage:
\nStore in a refrigerator at 2-8\u00b0C. Do not freeze or shake. Protect from light.<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name: \u62d3\u8fbe\u7ef4\u00ae(Trodelvy \u00ae)
\nGeneric Name: Sacituzumab Govitecan
\nStrength: 180mg per vial
\nManufacturer: BSP Pharmaceuticals S.p.A.
\nMarketing Authorization Holder: Gilead Sciences, Inc.
\nApproval Date in China: June 7, 2022
\nRegistration Number: \u56fd\u836f\u51c6\u5b57 SJ20220015
\nStorage: Store refrigerated at 2\u2103\uff5e8\u2103, protected from light, do not freeze. After reconstitution and dilution, prepare and administer promptly. Keep out of reach of children.<\/p>\n
Price&Cost:Contact Us now for the best price of Sacituzumab Govitecan(Trodelvy)<\/p>\n","protected":false},"featured_media":3425,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[25],"product_tag":[],"class_list":["post-3424","product","type-product","status-publish","has-post-thumbnail","product_cat-injection","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n